A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate
- PMID: 37354986
- DOI: 10.1016/j.jpag.2023.06.005
A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate
Abstract
Study objective: To describe satisfaction with and preference for subcutaneous depot medroxyprogesterone acetate (DMPA-SC), along with adherence and feasibility, in adolescents and young adults (AYAs) METHODS: Survey of a sample of AYA patients who received DMPA-SC prescription and injection RESULTS: Of 108 eligible patients, 34 completed the survey, and 29 respondents received at least 1 DMPA-SC injection. The mean age was 16.9 years. Seventy-nine point three percent used it for gynecologic reasons, 27.6% for gender dysphoria, and 20.7% for contraception (multiple responses allowed); 93.1% were satisfied with DMPA-SC; 78.6% gave DMPA-SC on time; 88.9% reported that giving the injection was easy; 89.7% reported no problems with administration; 89.3% reported no problems obtaining DMPA-SC; and 76.9% plan to continue using DMPA-SC.
Conclusion: In this small sample of patients within a children's hospital, the overall experience with DMPA-SC was favorable. Clinicians caring for adolescents should consider including DMPA-SC in counseling when depot medroxyprogesterone acetate (DMPA) is indicated.
Keywords: Adolescent; Contraceptive agents (female); Feasibility studies; Female; Humans; Injections (subcutaneous); Medroxyprogesterone acetate; Patient satisfaction; Young adult.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest HJW, EW, KJ, KS, OV, and AEB have no potential conflicts to disclose. EB received research funding from Merck and receives research funding from Organon, has been a consultant for Merck, and was a Nexplanon Clinical Trainer for Merck.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources